Bristol-Myers Squibb Company

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2024-04-23 pm EDT			Pre-market 07:00:09 am
48.99 ^USD	-0.31%		49.34	+0.72%

Apr. 23	Germany's Evotec appoints Christian Wojczewski as CEO	RE
Apr. 23	Novartis Nominates Former Bristol Myers Squibb CEO as New Chair	MT

BRISTOL MYERS SQUIBB CO : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)

February 24, 2020 at 05:16 pm EST

e>2020-02-20

id="c20200220to20200220_StatementClassOfStockAxis_One750NotesDue2035Member">

scheme="http://www.sec.gov/CIK">0000014272

dimension="us-gaap:StatementClassOfStockAxis">bmy:One750NotesDue2035Member2020-02-202020-02-20

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Latest news about Bristol-Myers Squibb Company

Germany's Evotec appoints Christian Wojczewski as CEO	Apr. 23	RE
Novartis Nominates Former Bristol Myers Squibb CEO as New Chair	Apr. 23	MT
Novartis Lifts 2024 Guidance as First-quarter Earnings Grow on Strong Blockbuster Drug Demand	Apr. 23	MT
Novartis raises targets for 2024	Apr. 23	CF
Alexandria Real Estate's Q1 FFO rises on stronger occupancy rates	Apr. 22	RE
Bristol-Myers Squibb Signs $380 Million Deal With Cellares to Manufacture CAR T Cell Therapies	Apr. 22	MT
Bristol Myers signs $380 mln CAR-T therapies supply deal with Cellares	Apr. 22	RE
Bristol Myers signs supply agreement with Cellares	Apr. 22	CF
Bristol Myers Squibb and Cellares reach $380 mln supply deal for CAR-T therapies	Apr. 22	RE
Bristol Myers Squibb and Cellares Announce Worldwide Capacity Reservation and Supply Agreement for Manufacture of CAR T Cell Therapies	Apr. 22	CI
Cantor Fitzgerald Adjusts Bristol-Myers Squibb's Price Target to $52 From $55, Maintains Neutral Rating	Apr. 22	MT
US FDA mandates label updates on CAR-T cancer therapies	Apr. 18	RE
Wells Fargo Adjusts Bristol-Myers Squibb's Price Target to $52 From $51, Keeps Equalweight Rating	Apr. 18	MT
Pathios Therapeutics Limited announced a financing transaction	Apr. 17	CI
TORL BioTherapeutics LLC announced that it has received $158.3 million in funding from a group of investors	Apr. 16	CI
Asher Biotherapeutics, Inc. announced that it has received $55 million in funding from a group of investors	Apr. 15	CI
Wolfe Research Adjusts Price Target on Bristol-Myers Squibb Company to $55 From $57, Outperform Rating Kept	Apr. 15	MT
Wolfe Research Adjusts Price Target on Bristol-Myers Squibb to $55 From $57, Maintains Outperform Rating	Apr. 15	MT
Jefferies Cuts Bristol-Myers Squibb's Price Target to $56 From $58	Apr. 12	MT
TORL BioTherapeutics LLC announces tranche update	Apr. 09	CI
Bristol Myers: cancer treatment results	Apr. 09	CF
Morgan Stanley Trims Price Target on Bristol-Myers Squibb to $40 From $41, Keeps Underweight Rating	Apr. 09	MT
Bristol Myers Squibb Announces KRAZATI in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer	Apr. 08	CI
Global markets live: Boeing, Shell, AstraZeneca, Tesla, Meta...	Apr. 08
Bristol Myers: new data on schizophrenia	Apr. 08	CF

Chart Bristol-Myers Squibb Company

Duration

Period

More charts

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

Pharmaceuticals

Calendar

2024-04-25 - Q1 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm EST

More Strategies

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

48.99 USD

Average target price

56.2 USD

Spread / Average Target

+14.71%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BRISTOL-MYERS SQUIBB COMPANY	-4.52%	99.29B
ELI LILLY AND COMPANY	+27.92%	672B
NOVO NORDISK A/S	+27.10%	570B
JOHNSON & JOHNSON	-4.59%	360B
MERCK & CO., INC.	+16.38%	321B
ABBVIE INC.	+9.39%	300B
ASTRAZENECA PLC	+7.35%	217B
NOVARTIS AG	+6.23%	199B
ROCHE HOLDING AG	-8.92%	204B
PFIZER, INC.	-8.58%	149B

Other Pharmaceuticals

Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Pharmaceuticals

BRISTOL MYERS SQUIBB CO : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)

Latest news about Bristol-Myers Squibb Company

Chart Bristol-Myers Squibb Company

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Bristol-Myers Squibb Company

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals